Silence Therapeutics PLC - American Depository Share (SLN) closed at $19.77 on November 11, 2026, down 0.1% from the previous close, on volume of 271,535 shares (30-day average 4,228,666).
Data as of November 11, 2026.
11-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 26, 2026 | Diagonal Call Spread | 15-Jan : 16-Apr-2715 : 20 C | 4,000 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
J&J gets into psychedelic treatments with backing of Delix Therapeutics
Seeking Alpha News (Mon, 9-Nov 12:12 PM ET)
Business Wire (Wed, 4-Nov 9:00 AM ET)
Globe Newswire (Thu, 22-Oct 10:29 AM ET)
Business Wire (Wed, 21-Oct 3:35 PM ET)
Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?
PRNewswire (Tue, 20-Oct 12:22 PM ET)
Business Wire (Mon, 19-Oct 9:40 AM ET)
Market Chameleon (Mon, 19-Oct 5:10 AM ET)
Business Wire (Mon, 19-Oct 8:00 AM ET)
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
Business Wire (Mon, 19-Oct 8:00 AM ET)
Silence Therapeutics to Participate in Three September Investor Conferences
Business Wire (Wed, 2-Sep 8:00 AM ET)
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Silence Therapeutics PLC - American Depository Share trades on the NASDAQ stock market under the symbol SLN.
As of November 11, 2026, SLN stock price declined to $19.77 with 271,535 million shares trading.
SLN has a beta of 1.17, meaning it tends to be more sensitive to market movements. SLN has a correlation of 0.02 to the broad based SPY ETF.
SLN has a market cap of $1.23 billion. This is considered a Small Cap stock.
Last quarter Silence Therapeutics PLC - American Depository Share reported $0 in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.06.
In the last 3 years, SLN traded as high as $27.72 and as low as $1.97.
The top ETF exchange traded funds that SLN belongs to (by Net Assets): IBB, GWX, APIE, IBBQ, BIB.
SLN has outperformed the market in the last year with a price return of +211.3% while the SPY ETF gained +12.6%. SLN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +28.1% and -0.1%, respectively, while the SPY returned -1.5% and -1.3%, respectively.
SLN support price is $19.16 and resistance is $20.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLN shares will trade within this expected range on the day.
